351 related articles for article (PubMed ID: 31924172)
1. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Feld JJ; Maan R; Zeuzem S; Kuo A; Nelson DR; Di Bisceglie AM; Manns MP; Sherman K; Frazier LM; Sterling R; Mailliard M; Schmidt M; Akushevich L; Vainorius M; Fried MW
Clin Infect Dis; 2016 Sep; 63(6):776-783. PubMed ID: 27325691
[TBL] [Abstract][Full Text] [Related]
3. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
Kang YW; Baek YH; Lee SW; Park SJ; Yoon JS; Yoon KT; Hong Y; Heo NY; Seo KI; Lee SS; Cho HC; Shin JW
J Korean Med Sci; 2021 May; 36(21):e142. PubMed ID: 34060258
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
5. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
[TBL] [Abstract][Full Text] [Related]
6. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Madera-Pajin R; Yunquera-Romero L; Muñoz-Castillo I
Rev Esp Quimioter; 2018 Feb; 31(1):35-42. PubMed ID: 29376623
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
[TBL] [Abstract][Full Text] [Related]
8. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan.
Mushtaq S; Akhter TS; Khan A; Sohail A; Khan A; Manzoor S
Front Pharmacol; 2020; 11():550205. PubMed ID: 32982753
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Mei YY; Chen YM; Wu YK; Zhang XH; Xu WX
Can J Gastroenterol Hepatol; 2020; 2020():8872120. PubMed ID: 33194875
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Örmeci N; Gülşen MT; Sezgin O; Aghayeva S; Demir M; Köksal I; Güner R; Erarslan E; Asiller ÖÖ; Balkan A; Yaraş S; Çalışkan Kartal A
Turk J Gastroenterol; 2020 Feb; 31(2):148-155. PubMed ID: 32141824
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Yee BE; Nguyen NH; Zhang B; Vutien P; Wong CR; Lutchman GA; Nguyen MH
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1189-201. PubMed ID: 25171028
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Flamm S; Lawitz E; Borg B; Charlton M; Landis C; Reddy KR; Shiffman M; Alsina A; Chang C; Ravendhran N; Hernandez C; Hézode C; Scherbakovsky S; Mercier RC; Samuel D
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896803
[TBL] [Abstract][Full Text] [Related]
15. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
Khaliq S; Raza SM
Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30400604
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
[TBL] [Abstract][Full Text] [Related]
17. Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.
Sahin A; Akay O
Ann Saudi Med; 2023; 43(5):308-314. PubMed ID: 37805816
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
19. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
Miranda AC; Mendez J; Serrão R; Vale F; Manata MJ; Pinto S; Gomes A; Valente C; Pacheco P; Pazos R; Pereira R; Martins A; Germano I; Rocha S; Reis AP; Sarmento-Castro R
J Viral Hepat; 2020 Jul; 27(7):715-720. PubMed ID: 32096268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
